Breast cancer is the most diagnosed female malignancy globally (23% of all cancers in females) with 15% mortality by this disease, as informed by GLOBOCAN for 2022. Our group has characterized the expression of α2-adrenergic receptors in breast cancer models. We have described that α2B (ADRA2B) and α2C (ADRA2C) are expressed in most of the cell lines and their stimulation is associated with cell proliferation and tumor growth while the stimulation of β2 (ADRB2) has the opposite effect. We have previously investigated GEO data for adrenergic receptor expression and its relationship with disease-free survival (DFS). The present investigation aimed to analyze TCGA and METABRIC databases to assess this relation. We found that ADRA2A expression was higher in luminal A, while ADRA2B was higher in basal-like in both databases. ADRB2 was lowest in the basal-like BrCa subtype. Then, we performed Kaplan Meier analysis for the data. Data from METABRIC patients revealed that high expression of ADRA2A was associated with significantly better DFS in luminal A and B, claudin-low and normal subtypes. TCGA data showed that only luminal A ADRA2A had this effect. ADRB2 high expression was associated with better DFS in luminal B and claudin-low tumors, while in TCGA only in the whole cohort, but lost significance when analyzing by subtypes (as previously seen in GEO). On the contrary, in METABRIC, ADRA2B high expression had a significantly lower DFS in luminal in general, HER2, claudin-low and normal. In TCGA the significantly lower DFS was in luminal A and basal. The previous study in GEO showed no effect of this receptor on DSF. For ADRA2C, a high expression was associated with lesser DFS in luminal B and claudin-low in METABRIC and none in TCGA. These results, with our previous on GEO ones, show that the results obtained interrogating different databases can vary, probably due to different ancestry, highlighting the importance of investigate several ones with different ancestry.